Articles from SmithRx

SmithRx, a modern pharmacy benefits manager (PBM) committed to transparency and a universal pass-through model, has been recognized by Modern Healthcare as one of the 2025 Best Places to Work in Healthcare. The award is based largely on employee feedback from a confidential survey administered by a third-party organization, and measures employee sentiment on key issues including growth opportunities, benefits, company culture, and more.

SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Program, including the introduction of Stelara biosimilars to its offering, new low-cost Humira and Stelara biosimilars for pediatric members, and a partnership with Costco Specialty Pharmacy alongside its long-standing relationship with Mark Cuban Cost Plus Drugs.

SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), this week published its newest report, “SmithRx: Milestones and Momentum in 2024,” which unveiled the company’s significant growth, cost savings, customer satisfaction, and market traction from 2024. The momentum SmithRx achieved over the past year is a direct result of the company’s commitment to challenging legacy models, driving innovation, and delivering value beyond dollars and cents – reflecting how SmithRx is building a new pharmacy benefits system that works for employers and employees alike.

SmithRx, a transparent and 100% pass-through pharmacy benefits manager (PBM), today shared new growth figures that showcase the company’s significant momentum and landmark achievements from the past year.

SmithRx, a transparent and 100% pass-through pharmacy benefits manager (PBM), today introduced a new PBM evaluation methodology – cost-based evaluation – optimized for lowering pharmacy benefits costs. Cost-based evaluation is detailed in SmithRx’s PBM Evaluation Guide, a comprehensive industry analysis unveiled today that offers an alternative path forward for pharmacy benefits management. Alongside the guide, the company also released new cost-savings data, which underscores how SmithRx’s cost-focused strategy results in a meaningful reduction in drug spend for employers – setting a new standard in the PBM industry.

SmithRx, a transparent and 100% pass-through PBM, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), announced today that in 6 months, they have saved SmithRx clients more than $9.5 million in the autoimmune category alone. This milestone has been achieved by strategically sourcing the lowest net cost autoimmune medications, including impactful transitions to cost-effective alternatives through Cost Plus Drugs.

SmithRx, a next-generation pharmacy benefits management (PBM) company, closed a $60M Series C financing round — building on the company’s $20M Series B round raised in 2022. Led by top Silicon Valley healthcare venture capital firm Venrock, the latest funding positions SmithRx to continue reducing costs of pharmacy benefits for small and midsize self-insured businesses.

Teaming up with Mark Cuban Cost Plus Drug Company, SmithRx will start offering members access beginning in July 2023

SmithRx, a next-generation pharmacy benefits management (PBM) company, has integrated Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) into its pharmacy network to expand access to affordable prescriptions for its members.